“…24 Consideration of digitalis is based on the modest symptomatic improvement seen in trials of adult patients with heart failure, even at relatively low doses. A recent prospective nonrandomized study in 102 children with congenital heart disease and DCM found that torasemide, a newer loop diuretic with potassium-sparing properties, significantly improved the New York University Pediatric Heart Failure Index, 49 decreased BNP levels, and improved fractional shortening, with no change in potassium or sodium levels in children who had not previously received diuretic therapy. 50 The largest improvements in clinical outcomes in studies of adults with heart failure have come from therapies that modify the neurohormonal milieu.…”